Pneumococcal Vaccination and Pneumonia: Even a Low Level of Clinical Effectiveness Is Highly Cost‐Effective | Zendy

André J.H.A. Ament | Zendy; David S. Fedson | Zendy; P Christie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pneumococcal Vaccination and Pneumonia: Even a Low Level of Clinical Effectiveness Is Highly Cost‐Effective

Author(s) -

André J.H.A. Ament,

David S. Fedson,

P Christie

Publication year - 2001

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/324356

Subject(s) - medicine , pneumonia , vaccination , pneumococcal pneumonia , pneumococcal vaccination , pneumococcal infections , immunology , intensive care medicine , pediatrics , streptococcus pneumoniae , antibiotics , microbiology and biotechnology , biology

Most studies of the cost-effectiveness of pneumococcal vaccination show very favorable cost-effectiveness ratios for preventing pneumococcal pneumonia, but they make the controversial assumption that vaccination is equally effective in preventing bacteremic (BPP) and nonbacteremic (NBPP) pneumonia. However, the results of our study showed that, compared with preventing BPP alone, the cost-effectiveness of pneumococcal vaccination increased substantially even when only a small proportion of additional cases of NBPP were prevented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research